<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04937153</url>
  </required_header>
  <id_info>
    <org_study_id>GCT1046-02</org_study_id>
    <nct_id>NCT04937153</nct_id>
  </id_info>
  <brief_title>GEN1046 Safety and PK in Subjects With Advanced Solid Malignancies</brief_title>
  <official_title>Open-label, Dose-escalation Trial to Evaluate the Safety and Pharmacokinetics of GEN1046 in Japanese Subjects With Advanced Solid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genmab</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioNTech SE</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Genmab</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single-country, multicenter, phase 1 dose escalation trial to assess&#xD;
      the safety and pharmacokinetics (PK) of GEN1046.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the trial is to evaluate the safety and pharmacokinetics of GEN1046 in&#xD;
      Japanese subjects with malignant solid tumors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2021</start_date>
  <completion_date type="Anticipated">November 13, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 13, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>The starting dose is 15 mg administered as a flat dose. Dose escalation steps are based on safety data.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity (DLT)</measure>
    <time_frame>DLTs are assessed during the first cycle (21 days) in each cohort</time_frame>
    <description>The occurrence of any toxicities as outlined in the protocol will be considered</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>AEs are collected up to 2 months after last subject last treatment</time_frame>
    <description>Incidence of treatment-emergent adverse events as assessed by CTCAE v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety laboratory parameters (hematology)</measure>
    <time_frame>Safety laboratory data are collected up to 2 months after last subject last treatment</time_frame>
    <description>Laboratory parameters graded by CTCAE v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety laboratory parameters (biochemistry)</measure>
    <time_frame>Safety laboratory data are collected up to 2 months after last subject last treatment</time_frame>
    <description>Laboratory parameters graded by CTCAE v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety laboratory parameters (coagulation)</measure>
    <time_frame>Safety laboratory data are collected up to 2 months after last subject last treatment</time_frame>
    <description>Laboratory parameters graded by CTCAE v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety laboratory parameters (endocrines)</measure>
    <time_frame>Safety laboratory data are collected up to 2 months after last subject last treatment</time_frame>
    <description>Laboratory parameters graded by CTCAE v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters</measure>
    <time_frame>PK data are collected until treatment discontinuation of the last subject</time_frame>
    <description>Predose trough concentrations (Ctrough)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters</measure>
    <time_frame>PK data are collected until treatment discontinuation of the last subject</time_frame>
    <description>Half-life (T1/2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters</measure>
    <time_frame>PK data are collected until treatment discontinuation of the last subject</time_frame>
    <description>Time of Cmax (Tmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters</measure>
    <time_frame>PK data are collected until treatment discontinuation of the last subject</time_frame>
    <description>Area-under-the-concentration-time curve (AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters</measure>
    <time_frame>PK data are collected until treatment discontinuation of the last subject</time_frame>
    <description>Maximum concentration (Cmax)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">7</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GEN1046 open label, single arm trial where GEN1046 will be administered</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GEN1046</intervention_name>
    <description>GEN1046 will be administered intravenously once every 21 days. The dose levels will be determined by the starting dose and the escalation steps taken in the trial.</description>
    <arm_group_label>Single arm</arm_group_label>
    <other_name>GEN1046 (DuoBody®-PD-L1x4-1BB)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Asian race and Japanese ethnicity&#xD;
&#xD;
          -  Have a histologically or cytologically confirmed non-CNS solid tumor that is&#xD;
             metastatic or unresectable and for whom there is no available standard therapy&#xD;
&#xD;
          -  Have measurable disease according to RECIST 1.1&#xD;
&#xD;
          -  Have Eastern Cooperative Oncology Group (ECOG) 0-1&#xD;
&#xD;
          -  Have an acceptable hematological status&#xD;
&#xD;
          -  Have acceptable liver function&#xD;
&#xD;
          -  Have an acceptable coagulation status&#xD;
&#xD;
          -  Have acceptable renal function&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Have uncontrolled intercurrent illness, including but not limited to:&#xD;
&#xD;
               -  Ongoing or active infection requiring intravenous treatment with anti-infective&#xD;
                  therapy&#xD;
&#xD;
               -  Symptomatic congestive heart failure (Grade III or IV as classified by the New&#xD;
                  York Heart Association), unstable angina pectoris or cardiac arrhythmia&#xD;
&#xD;
               -  Uncontrolled hypertension defined as systolic blood pressure ≥ 160 mmHg and/or&#xD;
                  diastolic blood pressure ≥ 100 mmHg, despite optimal medical management&#xD;
&#xD;
               -  Ongoing or recent evidence of autoimmune disease&#xD;
&#xD;
               -  History of irAEs that led to prior checkpoint treatment discontinuation&#xD;
&#xD;
               -  Prior history of myositis, Guillain-Barré syndrome, or myasthenia gravis of any&#xD;
                  grade&#xD;
&#xD;
               -  History of chronic liver disease or evidence of hepatic cirrhosis&#xD;
&#xD;
               -  History of non-infectious pneumonitis that has required steroids or currently has&#xD;
                  pneumonitis&#xD;
&#xD;
               -  History of organ allograft (except for corneal transplant) or autologous or&#xD;
                  allogeneic bone marrow transplant, or stem cell rescue within 3 months prior to&#xD;
                  the first dose of GEN1046&#xD;
&#xD;
               -  Serious, non-healing wound, skin ulcer (of any grade), or bone fracture&#xD;
&#xD;
          -  Any history of intracerebral arteriovenous malformation, cerebral aneurysm, new&#xD;
             (younger than 6 months) or progressive brain metastases or stroke&#xD;
&#xD;
          -  Prior therapy:&#xD;
&#xD;
               -  Radiotherapy: Radiotherapy within 14 days prior to first GEN1046 administration.&#xD;
                  Palliative radiotherapy will be allowed.&#xD;
&#xD;
               -  Treatment with an anti-cancer agent (within 28 days or after at least 5&#xD;
                  half-lives of the drug, whichever is shorter), prior to GEN1046 administration.&#xD;
                  Accepted exceptions are bisphosphonates (e.g., pamidronate, zoledronic acid,&#xD;
                  etc.) and denosumab&#xD;
&#xD;
          -  Toxicities from previous anti-cancer therapies that have not adequately resolved&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward Ramirez Ganoza, MD</last_name>
    <role>Study Director</role>
    <affiliation>Genmab</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Genmab Trial Information</last_name>
    <phone>+4570202728</phone>
    <email>clinicaltrials@genmab.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Cancer Center East</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 11, 2021</study_first_submitted>
  <study_first_submitted_qc>June 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2021</study_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

